Similar Search Results

Expected Profits and The Scientific Novelty of Innovation

Dranove, David - 2020

Innovation policy involves trading off monopoly output and pricing in the short run in exchange for incentives for …

Persistent link: https://www.econbiz.de/10012481677

The NBER Orange Book Dataset : A User's Guide

Durvasula, Maya; Hemphill, C. Scott; Ouellette, Lisa … - National Bureau of Economic Research - 2022

This paper introduces a newly digitized, open-access version of the Food and Drug Administration's "Orange Book"--a linkage between approved small-molecule drugs and the patents that protect them. The Orange Book also reports any applicable regulatory exclusivity that prevents competitive entry....

Persistent link: https://www.econbiz.de/10013462677

The Role of Assets In Place : Loss of Market Exclusivity and Investment

Higgins, Matthew J. - 2020

We utilize a novel identification strategy to analyze the impact of assets in place on firms' decisions for future projects. We exploit the context in the pharmaceutical industry, where the loss of market exclusivity for a branded drug can be used to separate the impact of cash flows generated...

Persistent link: https://www.econbiz.de/10012481442

Private and Social Returns to R&D : Drug Development and Demographics

Benmelech, Efraim; Eberly, Janice C.; Krieger, Joshua L.; … - National Bureau of Economic Research - 2021

Investment in intangible capital--in particular, research and development--increased dramatically since the 1990s. However, productivity growth remains sluggish in recent years. One potential reason is that a significant share of the increase in intangible investment is geared toward consumer...

Persistent link: https://www.econbiz.de/10012482573

The Future of Drug Development : The Economics of Pharmacogenomics

Vernon, John A. - 2005

This paper models how the evolving field of pharmacogenomics (PG), which is the science of using genomic markers to predict drug response, may impact drug development times, attrition rates, costs, and the future returns to research and development (R&D). While there still remains an abundance...

Persistent link: https://www.econbiz.de/10012466796

The Cost of US Pharmaceutical Price Reductions : A Financial Simulation Model of R&D Decisions

Abbott, Thomas A. - 2005

Previous empirical studies that have examined the links between pharmaceutical price controls, profits, cash flows, and investment in research and development (R&D) have been largely based on retrospective statistical analyses of firm- and/or industry-level data. These studies, which have...

Persistent link: https://www.econbiz.de/10012467571

Investigator Racial Diversity and Clinical Trial Participation

Alsan, Marcella; Campbell, Romaine A.; Leister, Lukas; … - National Bureau of Economic Research - 2023

We investigate whether increased racial diversity of clinical trial principal investigators could increase the enrollment of Black patients, which currently lags population and disease-burden shares. We conducted a survey experiment in which respondents were shown a photo of a current NIH...

Persistent link: https://www.econbiz.de/10014372489

Pharmaceutical Innovation, Mortality Reduction, and Economic Growth

Lichtenberg, Frank R. - 1998

We perform an econometric investigation of the contribution of pharmaceutical innovation to mortality reduction and … pharmaceutical innovation, there would have been no increase and perhaps even a small decrease in mean age at death, and that new … drugs have increased life expectancy, and lifetime income, by about 0.75-1.0% per annum. The drug innovation measures are …

Persistent link: https://www.econbiz.de/10012472240

The Effect of Pharmaceutical Utilization and Innovation on Hospitalization and Mortality

Lichtenberg, Frank R. - 1996

This paper presents an econometric analysis of the effect of changes in the quantity and type of pharmaceuticals prescribed by physicians in outpatient visits on rates of hospitalization, surgical procedure, mortality, and related variables. It examines the statistical relationship across...

Persistent link: https://www.econbiz.de/10012473446

Generics and New Goods in Pharmaceutical Price Indexes

Griliches, Zvi - 1993

We examine the issue of new goods and price indexes for the important and tractable case of generic and branded drugs. By treating generics as entirely distinct goods and "linking them in" to indexes with fixed weights, the standard price indexes fail to reflect the substantial welfare gains to...

Persistent link: https://www.econbiz.de/10012474690